

**NORTH CAROLINA MEDICAID AND NORTH CAROLINA HEALTH CHOICE PROGRAMS
PREFERRED DRUG LIST REVIEW PANEL**

October 29, 2012

Mr. Albert Delia
Secretary of Health and Human Services
N.C. Department of Health and Human Services
101 Blair Drive
Raleigh, N.C. 27603

Dear Secretary Delia,

On behalf of the North Carolina Department of Health and Human Services Medicaid and Health Choice Preferred Drug List Review Panel, I am pleased to present our annual recommendations to you for the North Carolina Medicaid and Health Choice Preferred Drug List. The following recommendations are from clinical reviews completed on September 25, 2012.

The panel reviewed drug classes on the proposed Preferred Drug List (PDL) that were approved by the Pharmacy and Therapeutics committee and the North Carolina Physician Advisory Group. The panel reviewed each drug class in which a decision was needed on preferred versus non-preferred status. Decisions were made with consideration given to the evidence-based data available for each drug class, the written comments received during the 45-day comment period and the public comments received during the panel meeting. The 45-day public comment period was from July 16, 2012 through August 28, 2012.

RECOMMENDATIONS:

The panel recommends approval of the proposed North Carolina Medicaid and Health Choice Preferred Drug List with associated prior authorization criteria as posted during the July 16, 2012 through August 28, 2012 public comment period with the following changes:

1. HEPATITIS C ANTIVIRALS

The panel approves the PDL proposal for HEPATITIS C ANTIVIRALS with the following change:

- Keep RibaPak a preferred medication.

2. PLATELET INHIBITORS

The panel approves the PDL proposal for PLATELET INHIBITORS with the following change:

- Utilize the Community Care of North Carolina to identify patients who leave an inpatient setting on Effient® to ensure coordination of care and continuation of therapy.
- Utilize the standard PA form for patients to obtain Effient when clinically needed and when genotyping has determined a patient to be a non-responder to clopidogrel.

3. MULTIPLE SCLEROSIS AGENTS

The panel approves the PDL proposal for MULTIPLE SCLEROSIS AGENTS with the following change:

- Keep Rebif® a preferred medication.
- Change Avonex Pen® to a preferred medication.
- Remove the injection site reaction criterion on this class.

4. AMYLIN ANALOGS

The panel approves the PDL proposal for AMYLIN ANALOGS with the following change:

- Keep both Symlin® and Symlin Pen® as preferred medications.

5. DPP-IV INHIBITORS AND COMBINATIONS

The panel approves the PDL proposal for DPP-IV INHIBITORS AND COMBINATIONS with the following change:

- Change Janumet XR®, Jentadueto®, and Juvisync® to preferred medications.

6. OPHTHALMIC ANTI-INFLAMMATORIES

The panel approves the PDL proposal for OPHTHALMIC ANTI-INFLAMMATORIES with the following change:

- Add the formulation description of “ointment” to the description of FML S.O.P.

7. BETA-ADRENERGIC SHORT-ACTING INHALERS

The panel approves the PDL proposal for BETA-ADRENERGIC SHORT-ACTING INHALERS with the following change:

- The implementation of these changes will not occur until April 1st, 2013

8. COPD AGENTS

The panel approves the PDL proposal for COPD AGENTS with the following change:

- Require only one trial and failure of a preferred agent to obtain Daliresp.

Sincerely,



Lisa Weeks, PharmD, RPh

Chair, Medicaid and Health Choice Preferred Drug List Review Panel

cc: Dr. Cedric Bright, Representative for the Old North State Medical Society
Dr. Paul Bush, Representative for Hospital-Based Pharmacy
Dr. Stefanie Ferreri, Representative for the North Carolina Association of Pharmacists
Dr. Theresa Flynn, Representative for the North Carolina Pediatric Society
Dr. Burt Johnson, Representative for the North Carolina Psychiatric Association

Dr. Byron Hoffman, Representative for the North Carolina Chapter of the American College of Physicians

Dr. Robert (Chuck) Rich, Representative for the North Carolina Academy of Family Physicians

Dr. William Sheridan, Representative for Research-Based Pharmaceutical Companies

Dr. Beat Steiner, Representative for the Physician Advisory Group Pharmacy and Therapeutics Committee

Dr. Tom Wroth, Representative for Community Care of North Carolina

Mr. Mike Watson, North Carolina Division of Medical Assistance

Ms. Tara Larson, North Carolina Division of Medical Assistance

Ms. Sandra Terrell, North Carolina Division of Medical Assistance

Dr. Randall Best, North Carolina Division of Medical Assistance

Mr. Jason Swartz, North Carolina Division of Medical Assistance